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Abstract: Recent studies have revealed that chronic inflammation represents a major basis for different forms of human malignancies. 
Chronic inflammations are involved in the pathogenesis of 15-25% of human malignancies. Gastrointestinal (GI) cancer is one of the 
most common causes of mortality in the European Union. The mechanisms leading to cancer development and its progression are not 
completely understood. Advances are required both in early detection and therapy of GI cancers. There are many factors connecting 
inflammation and cancer. Cytokines that are small protein molecules regulating growth, differentiation, development and immune 
response mechanisms in cells. Overexpression of cyclooxynenase-2 is associated with decreased apoptosis, cell to cell adhesion, 
increased proliferation and angiogenesis contributes to the increased immunosuppresion and mediates carcinogenetic effects. MicroRNAs 
are regarded as a novel class of gene expression regulators. They are gene-silencing RNAs which negatively regulate gene expression. 
After binding to target mRNAs they lead either to mRNA destruction or inhibition of translation. Hence, they can play an important role 
in carcinogenesis. Currently, almost all of the miRNA-related studies on cancers based on the different expression profile of miRNAs in 
cancer cells compared to normal cells.  
In summary, miRNAs, proinflammatory cytokines and other factors, may be involved in cancer development based on chronic 
inflammation by controlling cell differentiation and apoptosis. Assessing the role of miRNAs will provide the new insights on their 
contribution to the link between chronic inflammation and subsequent cancer, and new markers for cancer diagnoses and cancer therapy. 
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Recent studies have revealed that chronic inflammation 
represents a major basis for different forms of human malignancies. 
It was Rudolf Virchov in 1863, who for the first time proposed the 
role of inflammation in carcinogenesis as he noticed the presence of 
leukocytes in cancer tissues [1]. Chronic inflammations are 
involved in the pathogenesis of 15-25% of human malignancies [1, 
2]. Chronic inflammation that increased cancer risk comprise 
microbial infections like Helicobacter pylori (H. pylori) infection 
for gastric cancer, and autoimmune diseases (inflammatory bowel 
disease for colon cancer or Hashimoto thyroiditis for thyroid 
papillary carcinoma) [2, 3]. Gastrointestinal (GI) cancer is one of 
the most common causes of mortality in the European Union (EU) 
with 25% of mortality attributable to cancer and half of this due to 
GI cancer. The mechanisms leading to cancer development and its 
progression are not completely understood. Advances are required 
both in early detection and therapy of GI cancers. On the other 
hand, thyroid cancer is the most frequent endocrine neoplasia with 
rapidly increasing occurrence [3]. 
The possible mechanisms explaining how inflammation can 
contribute to carcinogenesis contain: 
 Induction of genomic instability, 
 Epigenetic changes resulting in inappropriate gene 
expression, 
 Resistance to apoptotic signals, 
 Increased proliferation and tumour vascularisation, 
 Overexpression of proinflammatory cytokines, 
cyclooxygenase-2 (COX-2), nitric oxide (NO) 
promoting tumour progression in its 
microenvironment, 
 Stromal cells in surrounding tissue and infiltrated 
immune cells activating proinflammatory cytokines,  
 MicroRNAs (miRNAs). 
In physiological conditions an inflammatory process act as a 
host defence against injury and is a self-limiting process [4]. 
However, inadequate and chronic inflammation often leads to 
cancers. 
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Table 1. Examples of Chronic Inflammation Leading to Cancer 
 
Inflammation Cancer 
Chronic pancreatitis Pancreatic cancer 
Barrett’s esophagitis Esophageal cancer 
Inflammatory bowel disease Colorectal cancer 
Chronic gastritis (Helicobacter pylori) Gastric cancer 
Thyroiditis Thyroid carcinoma 
Infection with HBV, HCV Hepatocellular carcinoma 
 
In response to proinflammatory stimuli immune cells can 
generate reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) [23]. Both ROS and RNS can act as effectors in 
inflammatory-related carcinogenesis [1-4]. Overproduction of ROS 
and RNS in the inflamed tissue leads to subsequent DNA damage: 
activation of oncogenes or inactivation of tumour suppressor genes 
[5]. Moreover ROS-induced DNA damages contain DNA strand 
breaks and DNA modifications resulting in replication errors 
contributing to cancer onset [6]. NO exerts its effect in 
inflammation-related carcinogenesis by direct modification of 
DNA. NO was also found to inactivate DNA repair enzymes [7]. 
The genomic DNA can be affected not only by direct 
mutational changes but also by epigenetic variations including 
DNA methylation and histone modifications [8]. DNA-methylation 
is the covalent addition of a methyl group to the 5-position of 
cytosine in the DNA [1]. DNA methylation is a critical epigenetic 
control of gene expression. The principal abnormal DNA 
methylation is hypermethylation that usually occurs in the promoter 
regions of tumour suppressor genes [8, 9]. Promoter 
hypermetylation of tumour suppressor genes i.e.: p16, p73, p53 
results in transcriptional silencing [8, 10]. Therefore 
hypermethylation of promoter sides leads to epigenetic silencing of 
tumour suppressor genes. As a result disturbances in cell cycle 
control, DNA repair, and cell adhesion can be observed and these 
processes are regarded to be crucial in carcinogenesis [9]. There are 
studies showing, that hypermethylation of E-cadherin gene in 
intestinal metaplasia in patients infected with H. pylori can be 
regarded as an early event in gastric cancer developing [11]. What’s 
more there are studies confirming that H. pylori infection is 
responsible for DNA hypermethylation of tumour suppressor p16 
gene [12]. This action strongly suggests impact of epigenetic 
changes in inflammatory-related cancers. 
134    Current Medicinal Chemistry,  2012 Vol. 19, No. 1 Ptak-Belowska et al. 
Other epigenetic mechanism regarded to control gene 
expression is chromatin remodelling by means of histone 
modification. Two enzymes: histone deacetylase (HDAC) and 
histone acetyl transferases (HATs) are involved in transcriptional 
regulation of many cancer-related genes [13]. It was shown that the 
inflammation-induced changes in histones may by due to an 
upregulation of proinflammatory cyclooksygenase-2 (COX-2) gene 
in human bronchial epithelial cells [14]. Moreover, the activation of 
NF-B, increased release of IL-6 and IL-8 in human alveolar cells 
were also related to increased acetylation of histone 4 [15]. Hence, 
the inflammation-related changes in histones and subsequent 
upregulation of NF-B, COX-2 and proinflammatory cytokines 
indicate that inflammation through epigenetic mechanisms may 
contribute to genetic instability of tumour cells. 
FACTORS CONNECTING INFLAMMATION AND CANCER 
Cytokines 
Cytokines are small protein molecules regulating growth, 
differentiation, development and immune response mechanisms in 
cells [16]. Cytokine signalling is pleiotropic as cross-regulation of 
one cytokine by other cytokine exists; different response by the 
same cytokine depends on a cell type [1]. Moreover, synergistic or 
antagonistic effects of cytokines are exerted by combine stimulation 
with other factors. Cytokines play an important role in the 
communication between cancer cells and surrounding environment 
(stromal tissue) promoting neoplasia progression [17, 18]. 
COX-2 and Prostaglandins 
Important enzymes involved in inflammation and tumour 
growth are cyclooxygenase (COX)-1 and COX-2. There are two 
isoforms of COX enzymes: constitutive COX-1 which is 
homeostatically expressed in most tissues and the inducible COX-2 
stimulated by various cytokines and growth factors and detectable 
in the inflamed tissues [19]. Overexpression of COX-2 is associated 
with decreased apoptosis, cell to cell adhesion, increased 
proliferation and angiogenesis contributes to the increased 
immunosuppresion and mediates carcinogenetic effects [19, 20]. 
iNOS and Nitric Oxide (NO) 
NO which is produced during arginine metabolism by different 
isoforms of NOS is an important factor connecting inflammation 
and cancer. During inflammation inducible form of NOS (iNOS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). MicroRNA biogenesis. Pri-miRNA transcripts are processed into pre-miRNAs by an enzymatic complex that includes the nuclear RNAse III enzyme 
Drosha and DGRC8. The resulting pre-miRNA is transported to the cytoplasm by exportin-5 and a Ran GTPase. Once in the cytoplasm, pre-miRNAs are 
processed into ~22-nucleotide duplexes by another RNAse III enzyme, Dicer, in association with TRBP. The strand corresponding to the mature miRNA is 
subsequently loaded onto the RISC. Mature miRNAs bind the 3'-untranslated region of target mRNAs and subsequently destabilize them, block their 
translation, or both.  
Abbreviations: DGRC8, DiGeorge syndrome critical region 8; mRNA, messenger RNA; miRNA, microRNA; pre-miRNA, precursor miRNA; pri-miRNA, 
primary miRNA; Ran, RAS-like nuclear protein; RISC, RNA-induced silencing complex; TRBP, trans-activation-response RNA-binding protein. 
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leads to production of NO [1, 21]. It is known that iNOS expression 
is regulated by several proinflammatory cytokines and it functions 
to generate high levels of NO via oxidative metabolism of L-
arginine. NO seems to have a dual role in colitis. On one hand, NO 
leads to vasodilatation, host defence and inhibition of neutrophil 
activation and platelet aggregation. On the other hand, NO is a 
highly reactive free radical and may rapidly react with active 
oxygen to generate peroxynitrate, which causes severe detrimental 
effects on colonic mucosa [21]. Moreover, it has been shown, that 
the level of NO and the expression on iNOS are elevated in 
numerous pre-cancer and neoplastic lesions [22].  
NF-B 
A large number of DNA-binding proteins are activated in 
response to inflammation [1, 3]. They can cause aberrant induction 
of numerous genes in neoplastic cells and in surrounding tissue 
cells. NF-B, a transcriptional factor, plays a crucial role in 
carcinogenesis, because its inproper activation contributes to 
tumorigenesis [1, 6]. Incorrect activation of NF-B leads to 
transactivation of target genes: inflammatory (e.g. COX-2, iNOS), 
anti-apoptotic (e.g. XIAP, Bcl-2), cell cycle regulating (cyclin D1) 
[1]. Therefore, NF-B has been recently identified as a crucial 
factor linking inflammation and cancer [24]. 
MiRNAs in Cancer Promotion 
MiRNAs are regarded as a novel class of gene expression 
regulators. The miRNAs are a family of non-coding, small size (19-
22 oligonucleotides) RNA fragments. They are gene-silencing 
RNAs which negatively regulate gene expression [25, 26]. After 
binding to target mRNAs they lead either to mRNA destruction or 
inhibition of translation [27]. There are studies suggesting that 
miRNAs can play an important role in carcinogenesis [25] because 
quite a lot of miRNAs have already been shown to act as oncogenes 
or tumour suppressor genes in numerous malignancies [28]. 
Currently, almost all of the miRNA-related studies on cancers 
based on the different expression profile of miRNAs in cancer cells 
compared to normal cells.  
The alterations in miRNA expression may play an important 
role in many diseases including: colorectal neoplasia (miR-143, 
miR-145), hepatocellular carcinoma (miR-18, miR-224, miR-199, 
miR-195, miR-200, miR-125), lung cancer (miR-17–92), papillary 
thyroid carcinoma (miR-221, miR-222, miR-146, miR-181), 
testicular germ cell tumours (miR-372, miR-373) [28, 33]. Due to 
its role in carcinogenesis miRNAs are also referred to as 
"oncomiRNas" [29, 30, 31,33] MicroRNAs are regarded to 
influence on cell proliferation, apoptosis, and metabolism and play 
a crucial role in chronic inflammation often leading to cancer [33]. 
Recently it was shown, that chronic inflammatory bowel diseases 
such as ulcerative colitis (UC) are associated with differential 
expression of genes involved in inflammation and tissue 
remodelling including miRNAs [34]. Decreased expression of miR-
192, was observed in active UC promoting colon cancer [34]. 
Therefore, expression profiles of specific miRNAs may be 
diagnostic and prognostic markers of many diseases including 
chronic inflammatory diseases leading to cancers. Because the role 
of miRNA in contribution to the link between inflammation and 
cancer has just been started to investigate uncovering the role of 
specific "oncomiRNas" seems to have promise in future research. 
Lately, miRNAs have been also studied as potential diagnostic 
or therapeutic targets in cancer treatment [35]. An association has 
been reported between miRNA expression in tumours and chemo- 
and radio sensitivity. Dissimilar miRNAs have been found to 
predict sensitivity to anticancer treatment e.g.: miR-30c, miR-130a 
and miR-335 are downregulated in various chemoresistant cell lines 
[35]. Therefore the role of miRNAs in carcinogenesis and on 
modification of anticancer treatment needs further investigation in 
order to asses the possible intracellular pathways involved in these 
processes. 
In summary, miRNAs, proinflammatory cytokines and other 
factors, may be involved in cancer development based on chronic 
inflammation by controlling cell differentiation and apoptosis. 
However, some miRNAs may be concerned in carcinogenesis by 
targeting cancer oncogenes and tumour suppressors. Assessing the 
role of miRNAs will provide the new insights on their contribution 
to the link between chronic inflammation and subsequent cancer, 
and new markers for cancer diagnoses and cancer therapy. 
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